Physician profile
Jilan Shah
NPI 1316092026
$24,284.82
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,837 · 2020: $7,302 · 2021: $5,779 · 2022: $3,197 · 2023: $147 · 2024: $23.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $169.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $22,299.69 | 2019-2024 | |
| Janssen Biotech, INC. | $473.60 | 2019-2022 | |
| Abbvie INC. | $398.39 | 2020-2023 | Mavyret |
| Viiv Healthcare Company | $376.43 | 2019-2022 | |
| Janssen Products, LP | $198.00 | 2019-2021 | |
| Emd Serono, INC. | $140.00 | 2019-2022 | |
| Astellas Pharma US INC | $99.00 | 2019 | |
| Allergan, INC. | $79.82 | 2019-2020 | |
| Shire North American Group INC | $73.74 | 2019 | |
| Melinta Therapeutics, LLC | $42.20 | 2019 | |
| Janssen Scientific Affairs, LLC | $23.71 | 2019 | |
| Merck Sharp & Dohme LLC | $22.51 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.25 | 2019 | |
| Insmed, INC. | $16.24 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.12 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion, INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jilan Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.